J K Groote

Summary

Affiliation: Netherlands Pharmacovigilance Centre Lareb
Country: The Netherlands

Publications

  1. ncbi [Side effects of sildenafil: findings from two years practical experience]
    A C van Grootheest
    Stichting Landelijke Registratie Evaluatie Bijwerkingen LAREB, Goudsbloemvallei 7, 5237 MH s Hertogenbosch
    Ned Tijdschr Geneeskd 145:526-9. 2001
  2. ncbi The role of hospital and community pharmacists in pharmacovigilance
    A C van Grootheest
    Netherlands Pharmacovigilance Centre Lareb, Hertogenbosch, The Netherlands
    Res Social Adm Pharm 1:126-33. 2005
  3. ncbi [Direct reporting of side effects by the patient: favourable experience in the first year]
    A C van Grootheest
    Nederlands Bijwerkingen Centrum Lareb, Goudsbloemvallei 7, 5237 MH s Hertogenbosch
    Ned Tijdschr Geneeskd 149:529-33. 2005
  4. ncbi Pharmacists' role in reporting adverse drug reactions in an international perspective
    Kees van Grootheest
    Netherlands Pharmacovigilance Centre Lareb, s Hertogenbosch, The Netherlands
    Pharmacoepidemiol Drug Saf 13:457-64. 2004
  5. ncbi Patients' role in reporting adverse drug reactions
    Kees van Grootheest
    The Netherlands Pharmacovigilance Centre Lareb, Goudsbloemvallei 7, 5237 MH s Hertogenbosch, The Netherlands
    Expert Opin Drug Saf 3:363-8. 2004
  6. ncbi Do pharmacists' reports of adverse drug reactions reflect patients' concerns?
    Kees van Grootheest
    Netherlands Pharmacovigilance Centre Lareb, Goudsbloemvallei 7, 5237 MH s Hertogenbosch, The Netherlands
    Pharm World Sci 26:155-9. 2004
  7. ncbi [Leopold Meyler (1903-1973): a pioneer in the field of side affects of drugs]
    A C van Grootheest
    Nederlands Bijwerkingen Centrum Lareb, Goudsbloemvallei 7, 5237 MH s Hertogenbosch
    Ned Tijdschr Geneeskd 147:2526-9. 2003
  8. ncbi Intensive monitoring of new drugs based on first prescription signals from pharmacists: a pilot study
    A C van Grootheest
    Netherlands Pharmacovigilance Centre Lareb, Goudsbloemvallei 7, 5237 MH s Hertogenbosch, The Netherlands
    Pharmacoepidemiol Drug Saf 12:475-81. 2003
  9. ncbi Consumer adverse drug reaction reporting: a new step in pharmacovigilance?
    Kees van Grootheest
    Netherlands Pharmacovigilance Centre Lareb, s Hertogenbosch, The Netherlands
    Drug Saf 26:211-7. 2003
  10. ncbi Thromboembolism associated with the new contraceptive Yasmin
    Kees van Grootheest
    Netherlands Pharmacovigilance Centre Lareb, Goudsbloemvallei 7, 5237 MH 's-Hertogenbosch, Netherlands
    BMJ 326:257. 2003

Collaborators

Detail Information

Publications13

  1. ncbi [Side effects of sildenafil: findings from two years practical experience]
    A C van Grootheest
    Stichting Landelijke Registratie Evaluatie Bijwerkingen LAREB, Goudsbloemvallei 7, 5237 MH s Hertogenbosch
    Ned Tijdschr Geneeskd 145:526-9. 2001
    ....
  2. ncbi The role of hospital and community pharmacists in pharmacovigilance
    A C van Grootheest
    Netherlands Pharmacovigilance Centre Lareb, Hertogenbosch, The Netherlands
    Res Social Adm Pharm 1:126-33. 2005
    ..If those involved in pharmaceutical disciplines can rise to this challenge, they will significantly help deepen our insights into ADRs...
  3. ncbi [Direct reporting of side effects by the patient: favourable experience in the first year]
    A C van Grootheest
    Nederlands Bijwerkingen Centrum Lareb, Goudsbloemvallei 7, 5237 MH s Hertogenbosch
    Ned Tijdschr Geneeskd 149:529-33. 2005
    ..To determine the results of establishing a station at which patients can report the side effects of drugs...
  4. ncbi Pharmacists' role in reporting adverse drug reactions in an international perspective
    Kees van Grootheest
    Netherlands Pharmacovigilance Centre Lareb, s Hertogenbosch, The Netherlands
    Pharmacoepidemiol Drug Saf 13:457-64. 2004
    ..Even today, there are a number of countries, in particular the Scandinavian countries, where pharmacists are not authorised to report ADRs. In those countries in which they are allowed to report, they do not always use this opportunity...
  5. ncbi Patients' role in reporting adverse drug reactions
    Kees van Grootheest
    The Netherlands Pharmacovigilance Centre Lareb, Goudsbloemvallei 7, 5237 MH s Hertogenbosch, The Netherlands
    Expert Opin Drug Saf 3:363-8. 2004
    ..The authors conclude that we should positively value patients' involvement in drug therapy and their concern regarding possible adverse effects. As a consequence, patients' reports on ADRs should be accepted...
  6. ncbi Do pharmacists' reports of adverse drug reactions reflect patients' concerns?
    Kees van Grootheest
    Netherlands Pharmacovigilance Centre Lareb, Goudsbloemvallei 7, 5237 MH s Hertogenbosch, The Netherlands
    Pharm World Sci 26:155-9. 2004
    ....
  7. ncbi [Leopold Meyler (1903-1973): a pioneer in the field of side affects of drugs]
    A C van Grootheest
    Nederlands Bijwerkingen Centrum Lareb, Goudsbloemvallei 7, 5237 MH s Hertogenbosch
    Ned Tijdschr Geneeskd 147:2526-9. 2003
    ..Had his voice been heeded earlier, the extent of the thalidomide disaster might well have been much more limited. His work still continues to contribute to the safe use of drugs...
  8. ncbi Intensive monitoring of new drugs based on first prescription signals from pharmacists: a pilot study
    A C van Grootheest
    Netherlands Pharmacovigilance Centre Lareb, Goudsbloemvallei 7, 5237 MH s Hertogenbosch, The Netherlands
    Pharmacoepidemiol Drug Saf 12:475-81. 2003
    ..Aim of this pilot study was to investigate the practical possibilities of a system of intensive monitoring, using the pharmacy computer system to detect the first dispensing of a new drug...
  9. ncbi Consumer adverse drug reaction reporting: a new step in pharmacovigilance?
    Kees van Grootheest
    Netherlands Pharmacovigilance Centre Lareb, s Hertogenbosch, The Netherlands
    Drug Saf 26:211-7. 2003
    ..To date, the data available are insufficient to establish such added value...
  10. ncbi Thromboembolism associated with the new contraceptive Yasmin
    Kees van Grootheest
    Netherlands Pharmacovigilance Centre Lareb, Goudsbloemvallei 7, 5237 MH 's-Hertogenbosch, Netherlands
    BMJ 326:257. 2003
  11. ncbi Labelling and 'Dear Doctor' letters: are they noncommittal?
    A C Kees van Grootheest
    Netherlands Pharmacovigilance Centre Lareb, s Hertogenbosch, The Netherlands
    Drug Saf 25:1051-5. 2002
    ..The dispensing pharmacist can play an important role in the implementation of warnings and contraindications...
  12. ncbi Contribution of pharmacists to the reporting of adverse drug reactions
    A C van Grootheest
    Netherlands Pharmacovigilance Foundation LAREB, Goudsbloemvallei 7, 5237 MH s Hertogenbosh, The Netherlands
    Pharmacoepidemiol Drug Saf 11:205-10. 2002
    ..The aim of the study is to get a better view about the possible contribution of pharmacists' reports to the quantity and the quality of reports and in this way to the quality of a voluntary reporting system of adverse drug reactions...
  13. ncbi Uterine perforation with the levonorgestrel-releasing intrauterine device: analysis of reports from four national pharmacovigilance centres
    Kees van Grootheest
    Netherlands Pharmacovigilance Centre Lareb, s Hertogenbosch, The Netherlands
    Drug Saf 34:83-8. 2011
    ..National pharmacovigilance centres have been receiving reports from healthcare professionals and patients of uterine perforation associated with the use of these LNG-IUDs...